{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5e81d0643b9a0dd40f9937b2/6a58c938c152a357db22eeae?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"EHA2026 | What are the key findings from the subgroup analysis of the EPCORE FL-1 trial in R/R FL? ","description":"<p>Following the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Lymphoma Hub spoke with Lorenzo Falchi, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What are the key findings from the subgroup analysis of the EPCORE FL-1 trial in R/R FL?&nbsp;</p><p>&nbsp;</p><p>This educational resource is independently supported by AbbVie. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.&nbsp;</p>","author_name":"Scientific Education Support"}